About Vigil Neuroscience
Vigil Neuroscience is a company based in Cambridge (United States) founded in 2020 was acquired by Sanofi in May 2025. It operates as a HealthTech. Vigil Neuroscience has raised $140 million across 3 funding rounds from investors including ARE, Sanofi and Citadel. The company has 56 employees as of February 28, 2023. Vigil Neuroscience offers products and services including TREM2 Activators. Vigil Neuroscience operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Dren Bio, among others.
- Headquarter Cambridge, United States
- Employees 56 as on 28 Feb, 2023
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vigil Neuroscience, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vigil Neuroscience
Vigil Neuroscience offers a comprehensive portfolio of products and services, including TREM2 Activators. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapeutics are developed to activate TREM2 in microglia.
Unlock access to complete
Unlock access to complete
Funding Insights of Vigil Neuroscience
Vigil Neuroscience has successfully raised a total of $140M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $40 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $40.0M
-
First Round
First Round
(08 Dec 2020)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Post-IPO - Vigil Neuroscience | Valuation |
investors |
|
| Aug, 2021 | Amount | Series B - Vigil Neuroscience | Valuation | Vida Ventures | |
| Dec, 2020 | Amount | Series A - Vigil Neuroscience | Valuation | Atlas Venture , Northpond Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Vigil Neuroscience
Vigil Neuroscience has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Sanofi and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biomedical innovations are transformed into therapies by Vida Ventures.
|
Founded Year | Domain | Location | |
|
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vigil Neuroscience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Vigil Neuroscience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vigil Neuroscience Comparisons
Competitors of Vigil Neuroscience
Vigil Neuroscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Dren Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vigil Neuroscience
Frequently Asked Questions about Vigil Neuroscience
When was Vigil Neuroscience founded?
Vigil Neuroscience was founded in 2020.
Where is Vigil Neuroscience located?
Vigil Neuroscience is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Vigil Neuroscience?
Ivana Magovcevic-Liebisch is the current CEO of Vigil Neuroscience.
Is Vigil Neuroscience a funded company?
Vigil Neuroscience is a funded company, having raised a total of $140M across 3 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on Dec 08, 2020.
How many employees does Vigil Neuroscience have?
As of Feb 28, 2023, the latest employee count at Vigil Neuroscience is 56.
What does Vigil Neuroscience do?
Vigil Neuroscience is engaged in developing disease-modifying therapeutics for rare and common neurodegenerative diseases by targeting microglia, the brains sentinel immune cells. The company is driven by a precision medicine approach, initially focusing on genetically defined patient subpopulations to activate and restore microglial function. Efforts are directed toward addressing high unmet needs in disease pathology, starting with rare diseases and expanding into more common neurodegenerative conditions. Therapeutic candidates are designed to activate TREM2, a key microglial receptor linked to brain health maintenance and neurodegeneration prevention.
Who are the top competitors of Vigil Neuroscience?
Vigil Neuroscience's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
What products or services does Vigil Neuroscience offer?
Vigil Neuroscience offers TREM2 Activators.
Who are Vigil Neuroscience's investors?
Vigil Neuroscience has 15 investors. Key investors include ARE, Sanofi, Citadel, Orbimed, and Atlas Venture.